Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction
with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic
hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active,
Relapsed or Refractory Acute Myeloid Leukemia (AML).